160 related articles for article (PubMed ID: 31708114)
21. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
23. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
24. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
25. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
[TBL] [Abstract][Full Text] [Related]
27. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
28. Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for Presurgical Assessment for Ovarian Cancer Risk.
Shulman LP; Francis M; Bullock R; Pappas T
Adv Ther; 2019 Sep; 36(9):2402-2413. PubMed ID: 31278693
[TBL] [Abstract][Full Text] [Related]
29. Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass.
Grenache DG; Heichman KA; Werner TL; Vucetic Z
Clin Chim Acta; 2015 Jan; 438():358-63. PubMed ID: 25283731
[TBL] [Abstract][Full Text] [Related]
30. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
31. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
[TBL] [Abstract][Full Text] [Related]
32. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.
Michalak M; Gąsiorowska E; Markwitz EN
Ginekol Pol; 2015 Apr; 86(4):256-61. PubMed ID: 26117983
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
Yang Y; Ju H; Huang Y
Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
[TBL] [Abstract][Full Text] [Related]
35. Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study.
Shen F; Lu S; Peng Y; Yang F; Chen Y; Lin Y; Yang C; Wu L; Li H; Zheng Y
Clin Chim Acta; 2017 Aug; 471():119-125. PubMed ID: 28549533
[TBL] [Abstract][Full Text] [Related]
36. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
37. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
39. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
[TBL] [Abstract][Full Text] [Related]
40. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.
Ikeda Y; Hasegawa K; Kurosaki A; Miyara A; Hanaoka T; Shintani D; Imai Y; Nishikawa T; Oda K; Fujiwara K
Oncol Res Treat; 2015; 38(6):276-81. PubMed ID: 26045023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]